Company / Current Assets
CytomX Therapeutics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$143.9M
FY2025
5-year range
$107.3M / $310.3M
FY2021-FY2025
Trend
+34.1%
vs FY2024
Sector context
#197 of 213
Health Care
What the data says
Among 213 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 8% for current assets. Current Assets returned to growth in FY2025 after 4 years of decline, reaching $144M.
Based on SEC 10-K filings.
$144M in FY2025 with a 5-year CAGR of -15.0%.
Declined from $183M to $144M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -15.3%
- 5-Year CAGR
- -15.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company $143.9M Sector average $2.5B
▼
-94.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.0%, indicating a declining trend.
- In FY2025, current assets increased 34.1% year-over-year.
- Ranks #197 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $143.9M | +34.1% |
| FY2024 | $107.3M | -41.3% |
| FY2023 | $182.9M | -22.8% |
| FY2022 | $237.1M | -23.6% |
| FY2021 | $310.3M | -4.2% |
| FY2020 | $324.0M | +6.8% |
| FY2019 | $303.3M | -31.9% |
| FY2018 | $445.5M | +14.6% |
| FY2017 | $388.6M | +106.5% |
| FY2016 | $188.1M | -0.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026